| NCT02791737 |
Exercise Prehab in Older Adults With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02791737 |
Active, not recruiting |
Ohio State University Comprehensive Cancer Center |
2020-12-31 |
| NCT03365791 |
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03365791 |
Active, not recruiting |
Novartis |
2019-02-21 |
| NCT04214093 |
A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors |
https://ClinicalTrials.gov/show/NCT04214093 |
Recruiting |
AstraZeneca |
2022-04-29 |
| NCT04035447 |
Symptom Management for YA Cancer Survivors |
https://ClinicalTrials.gov/show/NCT04035447 |
Recruiting |
Duke University |
2025-10-01 |
| NCT03955783 |
Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03955783 |
Recruiting |
Vanderbilt-Ingram Cancer Center |
2021-01-31 |
| NCT03373656 |
Vaccination for Children of H&O and Their Parents |
https://ClinicalTrials.gov/show/NCT03373656 |
Recruiting |
Children’s Cancer Group, China |
2019-09-30 |
| NCT03823651 |
A Research Program Targeting Pre- and Peri-transplant Optimization Program (R-PPOP) |
https://ClinicalTrials.gov/show/NCT03823651 |
Recruiting |
Duke University |
2021-01-31 |
| NCT03821519 |
Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT03821519 |
Recruiting |
A.O. Ospedale Papa Giovanni XXIII |
2022-05-31 |
| NCT03344705 |
Safety and Efficacy Evaluation of IM19 Cells |
https://ClinicalTrials.gov/show/NCT03344705 |
Recruiting |
Beijing Immunochina Medical Science & Technology Co., Ltd. |
2020-10-01 |
| NCT03328078 |
A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03328078 |
Recruiting |
Curis, Inc. |
2020-12-31 |
| NCT03320642 |
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease |
https://ClinicalTrials.gov/show/NCT03320642 |
Recruiting |
Incyte Corporation |
2020-07-31 |
| NCT03263637 |
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies |
https://ClinicalTrials.gov/show/NCT03263637 |
Active, not recruiting |
AstraZeneca |
2021-12-31 |
| NCT03248479 |
Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT03248479 |
Recruiting |
Forty Seven, Inc. |
2020-09-30 |
| NCT03219268 |
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms |
https://ClinicalTrials.gov/show/NCT03219268 |
Recruiting |
MacroGenics |
2020-06-30 |
| NCT03218683 |
Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. |
https://ClinicalTrials.gov/show/NCT03218683 |
Active, not recruiting |
AstraZeneca |
2022-01-11 |
| NCT03168815 |
Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic Bronchoscopy |
https://ClinicalTrials.gov/show/NCT03168815 |
Recruiting |
Mount Sinai Hospital, Canada |
2020-12-31 |
| NCT03162536 |
A Study of ARQ 531 in Patients With Selected Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03162536 |
Recruiting |
ArQule |
2021-12-31 |
| NCT03159702 |
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation |
https://ClinicalTrials.gov/show/NCT03159702 |
Recruiting |
Medical College of Wisconsin |
2021-07-01 |
| NCT03149055 |
Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT) |
https://ClinicalTrials.gov/show/NCT03149055 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-05-31 |
| NCT03145181 |
Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody, in Participants With Relapsed or Refractory Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT03145181 |
Recruiting |
Janssen Research & Development, LLC |
2021-03-29 |
| NCT03136445 |
TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia |
https://ClinicalTrials.gov/show/NCT03136445 |
Recruiting |
NHS Blood and Transplant |
2020-12-30 |
| NCT03133520 |
Effectiveness of High Flow Oxygen Therapy in Patients With Hematologic Malignancy Acute Hypoxemic Respiratory Failure |
https://ClinicalTrials.gov/show/NCT03133520 |
Completed |
TC Erciyes University |
2018-09-14 |
| NCT03131934 |
Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant |
https://ClinicalTrials.gov/show/NCT03131934 |
Recruiting |
University College, London |
2020-06-30 |
| NCT03128359 |
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT03128359 |
Recruiting |
City of Hope Medical Center |
2021-01-31 |
| NCT03125577 |
Combination CAR-T Cell Therapy Targeting Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT03125577 |
Recruiting |
Shenzhen Geno-Immune Medical Institute |
2019-07-31 |
| NCT03106662 |
Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT03106662 |
Completed |
Ankara University |
2017-07-31 |
| NCT03106428 |
A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT03106428 |
Completed |
MedImmune LLC |
2020-01-03 |
| NCT03096821 |
Extended Analysis for Leukemia/Lymphoma Treatment |
https://ClinicalTrials.gov/show/NCT03096821 |
Recruiting |
Medical University of Vienna |
2019-09-30 |
| NCT03094026 |
Cognitive Training Intervention and Attitudes Towards Genetics |
https://ClinicalTrials.gov/show/NCT03094026 |
Recruiting |
University of Alabama at Birmingham |
2024-07-31 |
| NCT03087227 |
Shared Health Information System for Febrile Neutropenia |
https://ClinicalTrials.gov/show/NCT03087227 |
Recruiting |
University of Paris 13 |
2019-11-30 |
| NCT03085173 |
A Trial of “Armored” CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03085173 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-03-31 |
| NCT03083327 |
Prophylactic Early PN in HPT/BMT |
https://ClinicalTrials.gov/show/NCT03083327 |
Recruiting |
University of Sydney |
2021-05-01 |
| NCT03082209 |
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03082209 |
Recruiting |
AbbVie |
2022-08-01 |
| NCT03067155 |
CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation. |
https://ClinicalTrials.gov/show/NCT03067155 |
Recruiting |
University Hospital, Ghent |
2022-12-31 |
| NCT03052777 |
Using Telephone Counselling to Improve Exercise Participation in Hematologic Cancer Survivors |
https://ClinicalTrials.gov/show/NCT03052777 |
Completed |
University of Alberta |
2017-08-01 |
| NCT03032783 |
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity |
https://ClinicalTrials.gov/show/NCT03032783 |
Recruiting |
Thomas Jefferson University |
2020-07-24 |
| NCT03023631 |
Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT03023631 |
Recruiting |
M.D. Anderson Cancer Center |
2020-04-30 |
| NCT02988466 |
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic |
https://ClinicalTrials.gov/show/NCT02988466 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2021-01-31 |
| NCT02966457 |
A Study of DEcolonization in Patients With HAematological Malignancies (DEHAM) |
https://ClinicalTrials.gov/show/NCT02966457 |
Completed |
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology |
2017-12-31 |
| NCT02964325 |
Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia |
https://ClinicalTrials.gov/show/NCT02964325 |
Recruiting |
Terumo BCTbio |
2021-11-30 |
| NCT02955966 |
PET/CT Guided Antifungal Stewardship in Invasive Pulmonary Aspergillosis |
https://ClinicalTrials.gov/show/NCT02955966 |
Recruiting |
Assistance Publique - Hôpitaux de Paris |
2020-08-31 |
| NCT02944045 |
Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients |
https://ClinicalTrials.gov/show/NCT02944045 |
Recruiting |
Assistance Publique - Hôpitaux de Paris |
2019-10-31 |
| NCT02924402 |
Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02924402 |
Recruiting |
Xencor, Inc. |
2020-08-31 |
| NCT02880709 |
The Effect of Special Diets in Hematological Cancer Patients |
https://ClinicalTrials.gov/show/NCT02880709 |
Completed |
University of Copenhagen |
2014-05-31 |
| NCT02880293 |
Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor |
https://ClinicalTrials.gov/show/NCT02880293 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-08-31 |
| NCT02849886 |
T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation. |
https://ClinicalTrials.gov/show/NCT02849886 |
Recruiting |
Centre Hospitalier Universitaire de Besancon |
2020-12-31 |
| NCT02841124 |
Decision to Limit or Withdraw Specific Therapies for Advanced Cancer and Hematological Malignancies. |
https://ClinicalTrials.gov/show/NCT02841124 |
Completed |
Centre Hospitalier Universitaire de Besancon |
2011-08-31 |
| NCT02834156 |
Impact of Child Positioning on Pain During a Lumbar Puncture |
https://ClinicalTrials.gov/show/NCT02834156 |
Completed |
Centre Hospitalier Universitaire de Nice |
2017-08-23 |
| NCT02828878 |
Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02828878 |
Recruiting |
Cellect Biotechnology |
2020-07-31 |
| NCT02813837 |
Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02813837 |
Recruiting |
Innovative Cellular Therapeutics Co., Ltd. |
2021-01-31 |
| NCT02805075 |
Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT02805075 |
Completed |
Stanford University |
2017-11-17 |
| NCT02745743 |
Phase I Trial of BAY1251152 for Advanced Blood Cancers |
https://ClinicalTrials.gov/show/NCT02745743 |
Completed |
Bayer |
2018-08-03 |
| NCT02743351 |
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02743351 |
Recruiting |
Fate Therapeutics |
2020-04-30 |
| NCT02730312 |
PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02730312 |
Recruiting |
Xencor, Inc. |
2020-08-31 |
| NCT02712905 |
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies |
https://ClinicalTrials.gov/show/NCT02712905 |
Recruiting |
Incyte Corporation |
2021-06-17 |
| NCT02711852 |
A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145) |
https://ClinicalTrials.gov/show/NCT02711852 |
Active, not recruiting |
Verastem, Inc. |
2020-06-30 |
| NCT02698189 |
A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005) |
https://ClinicalTrials.gov/show/NCT02698189 |
Active, not recruiting |
Merck Sharp & Dohme Corp. |
2018-01-18 |
| NCT02696408 |
Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation |
https://ClinicalTrials.gov/show/NCT02696408 |
Completed |
Institut de Cancérologie de la Loire |
2019-11-07 |
| NCT02684617 |
Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) |
https://ClinicalTrials.gov/show/NCT02684617 |
Completed |
Merck Sharp & Dohme Corp. |
2020-02-06 |
| NCT02680795 |
Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes |
https://ClinicalTrials.gov/show/NCT02680795 |
Recruiting |
Acrotech Biopharma LLC |
2021-03-31 |
| NCT02678338 |
CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies |
https://ClinicalTrials.gov/show/NCT02678338 |
Completed |
Forty Seven, Inc. |
2018-11-30 |
| NCT02668315 |
Expanded Cord Blood in Patients in Need of an Allogeneic Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT02668315 |
Completed |
Maisonneuve-Rosemont Hospital |
2018-08-31 |
| NCT02663518 |
A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors |
https://ClinicalTrials.gov/show/NCT02663518 |
Recruiting |
Trillium Therapeutics Inc. |
2021-06-30 |
| NCT02650791 |
Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study |
https://ClinicalTrials.gov/show/NCT02650791 |
Completed |
Ottawa Hospital Research Institute |
2019-06-30 |
| NCT02639559 |
Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT02639559 |
Active, not recruiting |
Washington University School of Medicine |
2018-04-12 |
| NCT02635984 |
Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens |
https://ClinicalTrials.gov/show/NCT02635984 |
Completed |
Augusta University |
2017-12-31 |
| NCT02634294 |
Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT |
https://ClinicalTrials.gov/show/NCT02634294 |
Recruiting |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2020-12-31 |
| NCT02623309 |
Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients |
https://ClinicalTrials.gov/show/NCT02623309 |
Recruiting |
Institut Paoli-Calmettes |
2019-02-28 |
| NCT02611063 |
Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT02611063 |
Recruiting |
Duke University |
2020-01-31 |
| NCT02600208 |
Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device |
https://ClinicalTrials.gov/show/NCT02600208 |
Recruiting |
Medical College of Wisconsin |
2020-12-31 |
| NCT02593123 |
Allogeneic Stem Cell Transplantationin Relapsed Hematological Malignancy: Early GVHD Prophylaxis |
https://ClinicalTrials.gov/show/NCT02593123 |
Active, not recruiting |
Virginia Commonwealth University |
2025-12-31 |
| NCT02583035 |
Telephone OncoGériatric Followed in the Management of Elderly Patients Treated for Cancer or Haematological Malignancy |
https://ClinicalTrials.gov/show/NCT02583035 |
Completed |
Centre Francois Baclesse |
2018-02-16 |
| NCT01028716 |
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01028716 |
Recruiting |
Fred Hutchinson Cancer Research Center |
2024-01-04 |
| NCT02576496 |
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02576496 |
Recruiting |
Mundipharma-EDO GmbH |
2021-03-31 |
| NCT02790515 |
Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation |
https://ClinicalTrials.gov/show/NCT02790515 |
Recruiting |
St. Jude Children’s Research Hospital |
2020-08-31 |
| NCT02376699 |
Safety Study of SEA-CD40 in Cancer Patients |
https://ClinicalTrials.gov/show/NCT02376699 |
Recruiting |
Seattle Genetics, Inc. |
2021-10-31 |
| NCT03403075 |
Therapeutic Education in Physical Activity (ETAF) |
https://ClinicalTrials.gov/show/NCT03403075 |
Completed |
Arcispedale Santa Maria Nuova-IRCCS |
2019-08-31 |
| NCT03399799 |
Dose Escalation Study of JNJ-64407564 in Participants With Relapsed or Refractory Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT03399799 |
Recruiting |
Janssen Research & Development, LLC |
2021-01-21 |
| NCT02566304 |
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02566304 |
Recruiting |
Thomas Jefferson University |
2020-07-23 |
| NCT02543879 |
Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02543879 |
Completed |
Forma Therapeutics, Inc. |
2019-03-31 |
| NCT02534649 |
Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials |
https://ClinicalTrials.gov/show/NCT02534649 |
Recruiting |
Institut Bergonié |
2020-03-31 |
| NCT02530034 |
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02530034 |
Recruiting |
M.D. Anderson Cancer Center |
2022-01-31 |
| NCT02514083 |
A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
https://ClinicalTrials.gov/show/NCT02514083 |
Active, not recruiting |
National Institutes of Health Clinical Center (CC) |
2019-10-02 |
| NCT02512666 |
Non Invasive Optical Imaging of WBC Count |
https://ClinicalTrials.gov/show/NCT02512666 |
Completed |
Massachusetts General Hospital |
2017-09-30 |
| NCT02508038 |
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors |
https://ClinicalTrials.gov/show/NCT02508038 |
Recruiting |
University of Wisconsin, Madison |
2021-05-31 |
| NCT02504047 |
Use of Haploidentical Related Donors for Patients Without Matched Sibling, Unrelated Donor or Cord Blood Units |
https://ClinicalTrials.gov/show/NCT02504047 |
Completed |
University of Calgary |
2019-02-01 |
| NCT02503033 |
A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02503033 |
Recruiting |
Hutchison Medipharma Limited |
2020-12-31 |
| NCT02500550 |
Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor |
https://ClinicalTrials.gov/show/NCT02500550 |
Completed |
Kiadis Pharma |
2018-07-31 |
| NCT02494258 |
A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders. |
https://ClinicalTrials.gov/show/NCT02494258 |
Active, not recruiting |
Celgene |
2021-02-28 |
| NCT02492789 |
A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients |
https://ClinicalTrials.gov/show/NCT02492789 |
Completed |
Atridia Pty Ltd. |
2019-03-01 |
| NCT02492737 |
Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation |
https://ClinicalTrials.gov/show/NCT02492737 |
Completed |
Agios Pharmaceuticals, Inc. |
2018-03-21 |
| NCT02487069 |
Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy |
https://ClinicalTrials.gov/show/NCT02487069 |
Completed |
Nanfang Hospital of Southern Medical University |
2020-01-31 |
| NCT02477878 |
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant |
https://ClinicalTrials.gov/show/NCT02477878 |
Active, not recruiting |
Bellicum Pharmaceuticals |
2018-03-26 |
| NCT02464696 |
Early Non Invasive Ventilation and Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT02464696 |
Recruiting |
M.D. Anderson Cancer Center |
2020-10-01 |
| NCT02443831 |
CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies |
https://ClinicalTrials.gov/show/NCT02443831 |
Active, not recruiting |
University College, London |
2020-10-31 |
| NCT02420873 |
An Open-label Phase II Study of Lorvotuzumab Mertansine |
https://ClinicalTrials.gov/show/NCT02420873 |
Completed |
M.D. Anderson Cancer Center |
2017-06-06 |
| NCT03386526 |
APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03386526 |
Recruiting |
Ascentage Pharma Group Inc. |
2020-09-11 |
| NCT02372357 |
A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area |
https://ClinicalTrials.gov/show/NCT02372357 |
Completed |
Universitaire Ziekenhuizen Leuven |
2014-08-31 |
| NCT02367196 |
A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers |
https://ClinicalTrials.gov/show/NCT02367196 |
Active, not recruiting |
Celgene |
2021-02-22 |
| NCT02362035 |
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02362035 |
Active, not recruiting |
Acerta Pharma BV |
2021-05-31 |
| NCT02361346 |
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL |
https://ClinicalTrials.gov/show/NCT02361346 |
Recruiting |
Molecular Templates, Inc. |
2021-05-31 |
| NCT02359838 |
Patient-Centered Care for the Older Adult With Hematologic Malignancy |
https://ClinicalTrials.gov/show/NCT02359838 |
Active, not recruiting |
Dana-Farber Cancer Institute |
2025-01-31 |
| NCT02352558 |
A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02352558 |
Completed |
Boston Biomedical, Inc |
2018-12-14 |
| NCT02342613 |
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02342613 |
Recruiting |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2023-01-31 |
| NCT02333162 |
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT02333162 |
Recruiting |
University of Chicago |
2020-12-01 |
| NCT02333058 |
Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies |
https://ClinicalTrials.gov/show/NCT02333058 |
Completed |
medac GmbH |
2016-12-24 |
| NCT02329847 |
A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02329847 |
Active, not recruiting |
Janssen Research & Development, LLC |
2020-07-31 |
| NCT02323867 |
Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02323867 |
Recruiting |
Children’s Hospital of Philadelphia |
2024-10-31 |
| NCT02321345 |
Pretransplant Evaluation by Supportive Care Team for Patients Undergoing HCT for Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT02321345 |
Completed |
Medical College of Wisconsin |
2017-10-31 |
| NCT02304809 |
Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations |
https://ClinicalTrials.gov/show/NCT02304809 |
Active, not recruiting |
UNICANCER |
2019-05-07 |
| NCT02270788 |
Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02270788 |
Completed |
St. Jude Children’s Research Hospital |
2016-10-17 |
| NCT02265731 |
Study Evaluating Venetoclax in Subjects With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT02265731 |
Active, not recruiting |
AbbVie |
2021-01-24 |
| NCT02223052 |
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02223052 |
Completed |
Celgene |
2018-06-11 |
| NCT02215070 |
Pasireotide in Prevention of GI Toxicity |
https://ClinicalTrials.gov/show/NCT02215070 |
Completed |
Duke University |
2019-02-28 |
| NCT02203903 |
Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies |
https://ClinicalTrials.gov/show/NCT02203903 |
Recruiting |
Children’s National Research Institute |
2024-11-30 |
| NCT02193880 |
Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT) |
https://ClinicalTrials.gov/show/NCT02193880 |
Completed |
University of Alabama at Birmingham |
2018-03-13 |
| NCT02167958 |
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source |
https://ClinicalTrials.gov/show/NCT02167958 |
Completed |
University of Pittsburgh |
2019-09-21 |
| NCT02160951 |
Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02160951 |
Completed |
Novartis |
2016-05-31 |
| NCT02149329 |
Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO |
https://ClinicalTrials.gov/show/NCT02149329 |
Completed |
VU University Medical Center |
2019-08-05 |
| NCT02145403 |
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02145403 |
Active, not recruiting |
University of Michigan Rogel Cancer Center |
2018-11-26 |
| NCT02139280 |
Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy |
https://ClinicalTrials.gov/show/NCT02139280 |
Active, not recruiting |
Dartmouth-Hitchcock Medical Center |
2019-07-31 |
| NCT02129582 |
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02129582 |
Active, not recruiting |
Case Comprehensive Cancer Center |
2019-03-15 |
| NCT02122081 |
Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02122081 |
Recruiting |
Ohio State University Comprehensive Cancer Center |
2019-12-31 |
| NCT02120157 |
Trial of Myeloablative Conditioning & Transplantation of Partially Human Leukocyte Antigen (HLA)-Mismatched Marrow With Post-transplant Cyclophosphamide for Peds Pts w/ Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02120157 |
Active, not recruiting |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2018-06-15 |
| NCT02106650 |
Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT02106650 |
Completed |
Acrotech Biopharma LLC |
2018-10-31 |
| NCT01351350 |
Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies |
https://ClinicalTrials.gov/show/NCT01351350 |
Completed |
Takeda |
2017-09-15 |
| NCT02074839 |
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation |
https://ClinicalTrials.gov/show/NCT02074839 |
Recruiting |
Agios Pharmaceuticals, Inc. |
2020-12-31 |
| NCT02074436 |
PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid) |
https://ClinicalTrials.gov/show/NCT02074436 |
Recruiting |
Emory University |
2021-05-31 |
| NCT02061761 |
Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02061761 |
Active, not recruiting |
Bristol-Myers Squibb |
2020-05-15 |
| NCT01317927 |
A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01317927 |
Completed |
Spectrum Pharmaceuticals, Inc |
2015-06-30 |
| NCT01315132 |
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01315132 |
Completed |
Thomas Jefferson University |
2018-09-19 |
| NCT02046291 |
Safety of Romiplostim (Nplate®) Following UCBT |
https://ClinicalTrials.gov/show/NCT02046291 |
Active, not recruiting |
Masonic Cancer Center, University of Minnesota |
2020-12-31 |
| NCT02038777 |
A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02038777 |
Active, not recruiting |
Pfizer |
2020-11-03 |
| NCT02034981 |
Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1 |
https://ClinicalTrials.gov/show/NCT02034981 |
Active, not recruiting |
UNICANCER |
2019-06-30 |
| NCT02032446 |
Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT02032446 |
Recruiting |
A.O. Ospedale Papa Giovanni XXIII |
2016-09-30 |
| NCT04018248 |
BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) |
https://ClinicalTrials.gov/show/NCT04018248 |
Recruiting |
Boryung Pharmaceutical Co., Ltd |
2023-12-31 |
| NCT01982682 |
Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor |
https://ClinicalTrials.gov/show/NCT01982682 |
Completed |
Thomas Jefferson University |
2017-03-27 |
| NCT01981187 |
LGX818 for Patients With BRAFV600 Mutated Tumors |
https://ClinicalTrials.gov/show/NCT01981187 |
Completed |
Array BioPharma |
2015-09-30 |
| NCT01943851 |
A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01943851 |
Completed |
GlaxoSmithKline |
2020-04-28 |
| NCT01930162 |
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant |
https://ClinicalTrials.gov/show/NCT01930162 |
Completed |
Novartis |
2016-08-29 |
| NCT01916057 |
Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis |
https://ClinicalTrials.gov/show/NCT01916057 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2017-06-01 |
| NCT01915498 |
Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation |
https://ClinicalTrials.gov/show/NCT01915498 |
Active, not recruiting |
Celgene |
2019-07-25 |
| NCT01912222 |
Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT01912222 |
Completed |
Millennium Pharmaceuticals, Inc. |
2015-03-31 |
| NCT01900509 |
Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01900509 |
Completed |
St. Jude Children’s Research Hospital |
2016-05-31 |
| NCT01888952 |
Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013) |
https://ClinicalTrials.gov/show/NCT01888952 |
Completed |
The University of Texas Health Science Center at San Antonio |
2015-01-31 |
| NCT01885897 |
IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT |
https://ClinicalTrials.gov/show/NCT01885897 |
Active, not recruiting |
Masonic Cancer Center, University of Minnesota |
2019-07-31 |
| NCT01885195 |
MEK162 for Patients With RAS/RAF/MEK Activated Tumors |
https://ClinicalTrials.gov/show/NCT01885195 |
Completed |
Array BioPharma |
2015-10-31 |
| NCT01854567 |
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01854567 |
Completed |
Mesoblast, Ltd. |
2016-09-23 |
| NCT01853358 |
Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT01853358 |
Completed |
Institut Paoli-Calmettes |
2018-03-15 |
| NCT01844869 |
An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate |
https://ClinicalTrials.gov/show/NCT01844869 |
Completed |
Teva Pharmaceutical Industries |
2014-12-31 |
| NCT01839916 |
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01839916 |
Completed |
University of Chicago |
2018-08-31 |
| NCT01830010 |
A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01830010 |
Completed |
Novartis |
2018-08-21 |
| NCT01827579 |
Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT) |
https://ClinicalTrials.gov/show/NCT01827579 |
Active, not recruiting |
University College, London |
2020-07-31 |
| NCT01810588 |
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation |
https://ClinicalTrials.gov/show/NCT01810588 |
Recruiting |
Weill Medical College of Cornell University |
2021-12-31 |
| NCT01807611 |
Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy |
https://ClinicalTrials.gov/show/NCT01807611 |
Active, not recruiting |
St. Jude Children’s Research Hospital |
2020-07-31 |
| NCT01802879 |
Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator |
https://ClinicalTrials.gov/show/NCT01802879 |
Completed |
Novartis |
2018-11-19 |
| NCT01799889 |
Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01799889 |
Completed |
Gilead Sciences |
2017-09-14 |
| NCT01794299 |
Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor |
https://ClinicalTrials.gov/show/NCT01794299 |
Completed |
Kiadis Pharma |
2016-06-30 |
| NCT01790568 |
Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01790568 |
Completed |
University of Michigan Rogel Cancer Center |
2017-01-01 |
| NCT01785810 |
Phase II Maraviroc for GVHD Prevention |
https://ClinicalTrials.gov/show/NCT01785810 |
Completed |
Abramson Cancer Center of the University of Pennsylvania |
2016-11-11 |
| NCT01767766 |
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01767766 |
Completed |
TG Therapeutics, Inc. |
2018-02-28 |
| NCT01760655 |
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01760655 |
Recruiting |
Thomas Jefferson University |
2021-03-31 |
| NCT01758484 |
Supportive Care for Patients With Hematological Malignancies Undergoing Hematopoietic Cell Transplant |
https://ClinicalTrials.gov/show/NCT01758484 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-11-30 |
| NCT01755000 |
Study of Hypotensive Hematopoietic Malignancy Patients’ USCOM Readings |
https://ClinicalTrials.gov/show/NCT01755000 |
Completed |
Washington University School of Medicine |
2013-04-30 |
| NCT01725555 |
A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors |
https://ClinicalTrials.gov/show/NCT01725555 |
Completed |
Axelar AB |
2013-12-31 |
| NCT01725022 |
A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care |
https://ClinicalTrials.gov/show/NCT01725022 |
Completed |
Duke University |
2017-09-30 |
| NCT01724528 |
Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01724528 |
Completed |
Menarini Group |
2013-10-31 |
| NCT01687231 |
Infection Rates of Myeloablative Allo SCT Recipients Receiving Neutropenic Diets Versus Non-Neutropenic Diets |
https://ClinicalTrials.gov/show/NCT01687231 |
Completed |
Duke University |
2011-12-31 |
| NCT01682226 |
Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01682226 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2020-09-30 |
| NCT01664910 |
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01664910 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2021-10-31 |
| NCT01658319 |
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01658319 |
Completed |
Case Comprehensive Cancer Center |
2015-02-28 |
| NCT01635712 |
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01635712 |
Completed |
Esanex Inc. |
2016-01-31 |
| NCT01627275 |
Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01627275 |
Completed |
Duke University |
2017-02-24 |
| NCT01607892 |
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer |
https://ClinicalTrials.gov/show/NCT01607892 |
Completed |
Karyopharm Therapeutics Inc |
2016-06-30 |
| NCT01606033 |
Study of Stress and Life Quality of Patients Participating in Clinical Trials Versus Patients Non Participating |
https://ClinicalTrials.gov/show/NCT01606033 |
Completed |
Centre Oscar Lambret |
2014-01-31 |
| NCT01597219 |
Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers |
https://ClinicalTrials.gov/show/NCT01597219 |
Active, not recruiting |
University College, London |
2019-10-31 |
| NCT01596257 |
Bulk Versus Fractionated Stem Cell Infusions in Patients With Hematologic Malignancies Undergoing Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT01596257 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-05-31 |
| NCT01594723 |
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms |
https://ClinicalTrials.gov/show/NCT01594723 |
Active, not recruiting |
Eli Lilly and Company |
2015-03-20 |
| NCT01576653 |
Prospective Clinical Evaluation of Beta-D-Glucan Assay in Blood and BAL |
https://ClinicalTrials.gov/show/NCT01576653 |
Recruiting |
Medical University of Graz |
2019-06-30 |
| NCT01572181 |
Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens |
https://ClinicalTrials.gov/show/NCT01572181 |
Completed |
Nantes University Hospital |
2017-10-24 |
| NCT01553461 |
Transplants With Unlicensed Preserved Cord Blood |
https://ClinicalTrials.gov/show/NCT01553461 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2036-10-20 |
| NCT01551524 |
Phase I Study of mPEG-R-Crisantaspase Given IV |
https://ClinicalTrials.gov/show/NCT01551524 |
Completed |
Jazz Pharmaceuticals |
2015-02-28 |
| NCT01531894 |
Continuation Study of the Oral AKT Inhibitor GSK2110183 |
https://ClinicalTrials.gov/show/NCT01531894 |
Completed |
Novartis |
2018-06-20 |
| NCT01530581 |
Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation |
https://ClinicalTrials.gov/show/NCT01530581 |
Completed |
King Faisal Specialist Hospital & Research Center |
2012-06-30 |
| NCT01523171 |
Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib |
https://ClinicalTrials.gov/show/NCT01523171 |
Completed |
Sanofi |
2014-04-30 |
| NCT01499147 |
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01499147 |
Completed |
University of Illinois at Chicago |
2013-05-31 |
| NCT01491958 |
Safety & Efficacy of Atorvastatin for Prophylaxis of Acute Graft Versus Host Disease in Patients With Hematological Malignancies HLA- Donor Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT01491958 |
Completed |
Ohio State University Comprehensive Cancer Center |
2014-01-01 |
| NCT01484470 |
Umbilical Cord Transplantation for the Elderly Population |
https://ClinicalTrials.gov/show/NCT01484470 |
Completed |
Loyola University |
2018-11-21 |
| NCT01474681 |
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01474681 |
Completed |
Novartis |
2016-10-03 |
| NCT01471067 |
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01471067 |
Completed |
M.D. Anderson Cancer Center |
2017-04-25 |
| NCT01460719 |
A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013) |
https://ClinicalTrials.gov/show/NCT01460719 |
Completed |
Merck Sharp & Dohme Corp. |
2012-09-25 |
| NCT01460420 |
Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation |
https://ClinicalTrials.gov/show/NCT01460420 |
Completed |
European Myeloma Network |
2017-06-30 |
| NCT01451502 |
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units |
https://ClinicalTrials.gov/show/NCT01451502 |
Recruiting |
Masonic Cancer Center, University of Minnesota |
2022-12-31 |
| NCT01437787 |
Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01437787 |
Completed |
Sanofi |
2014-06-30 |
| NCT01428973 |
Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens |
https://ClinicalTrials.gov/show/NCT01428973 |
Active, not recruiting |
University of Liege |
2022-09-30 |
| NCT01420783 |
Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia |
https://ClinicalTrials.gov/show/NCT01420783 |
Completed |
Sanofi |
2012-11-30 |
| NCT01420770 |
Phase 2 Study of SAR302503 in Patients With Myelofibrosis |
https://ClinicalTrials.gov/show/NCT01420770 |
Completed |
Sanofi |
2014-04-30 |
| NCT01416428 |
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01416428 |
Completed |
Amgen |
2019-08-12 |
| NCT01380756 |
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia |
https://ClinicalTrials.gov/show/NCT01380756 |
Completed |
Amgen |
2014-09-04 |
| NCT01375842 |
A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors |
https://ClinicalTrials.gov/show/NCT01375842 |
Completed |
Genentech, Inc. |
2018-09-30 |
| NCT01374841 |
Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors |
https://ClinicalTrials.gov/show/NCT01374841 |
Recruiting |
European Institute of Oncology |
2019-08-31 |
| NCT01353625 |
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. |
https://ClinicalTrials.gov/show/NCT01353625 |
Active, not recruiting |
Celgene |
2020-12-28 |
| NCT01349101 |
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors |
https://ClinicalTrials.gov/show/NCT01349101 |
Recruiting |
Thomas Jefferson University |
2020-12-31 |
| NCT01345019 |
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01345019 |
Completed |
Amgen |
2016-07-19 |
| NCT01344876 |
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01344876 |
Completed |
Otsuka Pharmaceutical Co., Ltd. |
2014-04-30 |
| NCT01344707 |
Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS) |
https://ClinicalTrials.gov/show/NCT01344707 |
Completed |
4SC AG |
2015-03-31 |
| NCT01341301 |
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01341301 |
Completed |
Thomas Jefferson University |
2013-11-04 |
| NCT01334060 |
WT1 Immunity Via DNA Fusion Gene Vaccination in Haematological Malignancies by Intramuscular Injection Followed by Intramuscular Electroporation |
https://ClinicalTrials.gov/show/NCT01334060 |
Completed |
University Hospital Southampton NHS Foundation Trust |
2013-02-28 |
| NCT01332006 |
Intra-bone Cord Blood Transplantation |
https://ClinicalTrials.gov/show/NCT01332006 |
Recruiting |
Università degli Studi di Brescia |
2019-12-31 |
| NCT01328496 |
Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen |
https://ClinicalTrials.gov/show/NCT01328496 |
Completed |
St. Jude Children’s Research Hospital |
2016-10-31 |
| NCT01324323 |
Influence of Rifampin on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer |
https://ClinicalTrials.gov/show/NCT01324323 |
Completed |
Celgene |
2012-02-01 |
| NCT01324310 |
Influence of Ketoconazole on the Pharmacokinetics of Romidepsin in Patients With Advanced Cancer |
https://ClinicalTrials.gov/show/NCT01324310 |
Completed |
Celgene |
2012-01-01 |
| NCT01321346 |
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01321346 |
Completed |
Therapeutic Advances in Childhood Leukemia Consortium |
2015-10-31 |
| NCT04425642 |
Effects of Parenteral Nutrition in HSCT |
https://ClinicalTrials.gov/show/NCT04425642 |
Recruiting |
St. Petersburg State Pavlov Medical University |
2020-11-01 |
| NCT04347226 |
Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19 |
https://ClinicalTrials.gov/show/NCT04347226 |
Recruiting |
Columbia University |
2021-09-30 |
| NCT04331483 |
A Study to Assess a Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Allografts |
https://ClinicalTrials.gov/show/NCT04331483 |
Active, not recruiting |
Centre Leon Berard |
2023-09-30 |
| NCT04310592 |
Natural Killer Cell (CYNK-001) Infusions in Adults With AML |
https://ClinicalTrials.gov/show/NCT04310592 |
Recruiting |
Celularity Incorporated |
2022-01-03 |
| NCT04283097 |
Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects |
https://ClinicalTrials.gov/show/NCT04283097 |
Recruiting |
Kangpu Biopharmaceuticals, Ltd. |
2021-12-30 |
| NCT04283006 |
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT04283006 |
Recruiting |
Zhejiang University |
2023-05-23 |
| NCT04280133 |
CAR T-CELL Therapy Educational Video Trial |
https://ClinicalTrials.gov/show/NCT04280133 |
Recruiting |
Massachusetts General Hospital |
2021-12-31 |
| NCT04227015 |
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy |
https://ClinicalTrials.gov/show/NCT04227015 |
Recruiting |
Zhejiang University |
2022-01-08 |
| NCT04226989 |
A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy |
https://ClinicalTrials.gov/show/NCT04226989 |
Recruiting |
Zhejiang University |
2022-02-05 |
| NCT04205409 |
Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT04205409 |
Recruiting |
University of Washington |
2022-08-01 |
| NCT04191941 |
Treatment of Hematological Malignancy With Novel CAR-T Cells. |
https://ClinicalTrials.gov/show/NCT04191941 |
Recruiting |
Timmune Biotech Inc. |
2021-08-31 |
| NCT04191187 |
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT04191187 |
Recruiting |
H. Lee Moffitt Cancer Center and Research Institute |
2022-12-31 |
| NCT04184869 |
Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials |
https://ClinicalTrials.gov/show/NCT04184869 |
Recruiting |
Acrotech Biopharma LLC |
2022-06-01 |
| NCT04184414 |
The Clinical Application of Chimeric Antigen Receptor T Cells in the Treatment of CD19 Positive Recurrent Refractory B Cell-derived Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT04184414 |
Recruiting |
PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
2020-01-01 |
| NCT04174053 |
Concordance Between 2 Means of Temperature Measure in Neutropenic Patients Hospitalized in Intensive Hematology Care Units |
https://ClinicalTrials.gov/show/NCT04174053 |
Recruiting |
Centre Henri Becquerel |
2020-06-30 |
| NCT04156256 |
CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT04156256 |
Recruiting |
iCell Gene Therapeutics |
2020-09-30 |
| NCT04103879 |
US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia |
https://ClinicalTrials.gov/show/NCT04103879 |
Recruiting |
ExCellThera inc. |
2021-12-31 |
| NCT04098393 |
Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT04098393 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-09-30 |
| NCT04068597 |
Study to Evaluate CCS1477 in Haematological Malignancies |
https://ClinicalTrials.gov/show/NCT04068597 |
Recruiting |
CellCentric Ltd. |
2020-12-31 |
| NCT04057443 |
Nutritional and Physical Exercise Intervention in Older Patients With Malignant Hemopathies |
https://ClinicalTrials.gov/show/NCT04057443 |
Recruiting |
L’Hospitalet de Llobregat |
2021-06-01 |
| NCT04052126 |
An Individualized Physical Activity Program in Patients Over 65 Years With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT04052126 |
Recruiting |
Centre Leon Berard |
2021-02-28 |
| NCT04024618 |
Feasibility Study Comparing Enteral vs Parenteral Nutritional Outcomes in Autologous Stem Cell Transplant Patients |
https://ClinicalTrials.gov/show/NCT04024618 |
Recruiting |
Lawson Health Research Institute |
2020-08-30 |
| NCT04022239 |
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT04022239 |
Recruiting |
M.D. Anderson Cancer Center |
2022-07-01 |
| NCT04013685 |
A Study of Engineered Donor Grafts (TregGraft) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT04013685 |
Recruiting |
Orca Biosystems, Inc. |
2022-09-30 |
| NCT04011293 |
A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies |
https://ClinicalTrials.gov/show/NCT04011293 |
Recruiting |
Shandong University |
2020-07-31 |
| NCT03983850 |
Optimizing PTCy Dose and Timing |
https://ClinicalTrials.gov/show/NCT03983850 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2024-05-31 |
| NCT03963024 |
Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT |
https://ClinicalTrials.gov/show/NCT03963024 |
Recruiting |
IRCCS San Raffaele |
2019-12-31 |
| NCT03961919 |
Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant |
https://ClinicalTrials.gov/show/NCT03961919 |
Active, not recruiting |
IRCCS San Raffaele |
2019-12-31 |
| NCT03960619 |
In Person and Mobile Health Coping Skills Training for Improving Symptom Management and Daily Steps in Hematopoietic Stem Cell Transplant Patients |
https://ClinicalTrials.gov/show/NCT03960619 |
Completed |
Duke University |
2019-11-22 |
| NCT03922035 |
CBM588 in Improving Clinical Outcomes in Patients Who Have Undergone Donor Hematopoietic Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT03922035 |
Recruiting |
City of Hope Medical Center |
2021-12-24 |
| NCT03919214 |
Hypertension Management in Cancer Patients |
https://ClinicalTrials.gov/show/NCT03919214 |
Recruiting |
Duke University |
2020-12-31 |
| NCT03913949 |
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03913949 |
Recruiting |
Ascentage Pharma Group Inc. |
2021-03-31 |
| NCT03913026 |
UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia |
https://ClinicalTrials.gov/show/NCT03913026 |
Recruiting |
Ciusss de L’Est de l’ÃŽle de Montréal |
2023-12-31 |
| NCT03908138 |
RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT03908138 |
Recruiting |
Shandong Provincial Hospital |
2021-12-31 |
| NCT03903185 |
Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy |
https://ClinicalTrials.gov/show/NCT03903185 |
Recruiting |
Ain Shams University |
2021-03-31 |
| NCT03886831 |
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03886831 |
Recruiting |
Prelude Therapeutics |
2021-08-11 |
| NCT03885947 |
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT03885947 |
Recruiting |
Icahn School of Medicine at Mount Sinai |
2021-01-17 |
| NCT03882203 |
CLAME Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia |
https://ClinicalTrials.gov/show/NCT03882203 |
Recruiting |
Shanghai Jiao Tong University School of Medicine |
2021-08-30 |
| NCT03850366 |
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib |
https://ClinicalTrials.gov/show/NCT03850366 |
Recruiting |
Henry Ford Health System |
2023-01-01 |
| NCT03849651 |
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03849651 |
Recruiting |
St. Jude Children’s Research Hospital |
2024-07-01 |
| NCT03844360 |
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease |
https://ClinicalTrials.gov/show/NCT03844360 |
Recruiting |
Shandong University |
2021-12-31 |
| NCT03837899 |
Durvalumab and Tremelimumab for Pediatric Malignancies |
https://ClinicalTrials.gov/show/NCT03837899 |
Recruiting |
AstraZeneca |
2021-10-18 |
| NCT03837171 |
TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock |
https://ClinicalTrials.gov/show/NCT03837171 |
Recruiting |
Assistance Publique - Hôpitaux de Paris |
2021-02-20 |
| NCT03818334 |
Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT03818334 |
Recruiting |
Hospital Israelita Albert Einstein |
2021-11-01 |
| NCT03812705 |
Fecal Microbiota Transplantation for Steroid Resistant/Dependent Acute GI GVHD |
https://ClinicalTrials.gov/show/NCT03812705 |
Recruiting |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2022-12-31 |
| NCT03806764 |
Cytomegalovirus (CMV) Reactivation in Allogeneic HSCT Recipient |
https://ClinicalTrials.gov/show/NCT03806764 |
Enrolling by invitation |
Melbourne Health |
2020-03-31 |
| NCT03804164 |
Psycho-Educational Cognition Intervention in Patients With Blood and Lymph Cancer |
https://ClinicalTrials.gov/show/NCT03804164 |
Recruiting |
City of Hope Medical Center |
2020-06-24 |
| NCT03802695 |
A Phase 1 Study of Engineered Donor Grafts (OrcaGraft) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03802695 |
Recruiting |
Orca Biosystems, Inc. |
2022-07-01 |
| NCT03801122 |
Evolution of Thromboelastography During Tranexamic Acid Treatment |
https://ClinicalTrials.gov/show/NCT03801122 |
Recruiting |
Institut de Cancérologie de la Loire |
2021-01-01 |
| NCT03800758 |
Expressive Helping for Stem Cell Transplant Patients |
https://ClinicalTrials.gov/show/NCT03800758 |
Recruiting |
Northwestern University |
2022-06-30 |
| NCT03795779 |
CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03795779 |
Recruiting |
iCell Gene Therapeutics |
2020-09-30 |
| NCT03783403 |
A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers |
https://ClinicalTrials.gov/show/NCT03783403 |
Recruiting |
Celgene |
2022-12-30 |
| NCT03765177 |
CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03765177 |
Recruiting |
Ottawa Hospital Research Institute |
2022-10-31 |
| NCT03757000 |
A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03757000 |
Recruiting |
Shanghai YingLi Pharmaceutical Co. Ltd. |
2019-03-30 |
| NCT03743480 |
Early Palliative Care and Hematological Cancer Patients |
https://ClinicalTrials.gov/show/NCT03743480 |
Recruiting |
Arcispedale Santa Maria Nuova-IRCCS |
2020-11-30 |
| NCT03735992 |
Mind-body Medicine for Patients With Malignant Hematological Diseases |
https://ClinicalTrials.gov/show/NCT03735992 |
Recruiting |
Universität Duisburg-Essen |
2020-12-30 |
| NCT03733340 |
Antibacterial Prophylaxis vs no Prophylaxis for Hematological Malignancies Patients Before Allo-HSCT |
https://ClinicalTrials.gov/show/NCT03733340 |
Recruiting |
Nanfang Hospital of Southern Medical University |
2019-12-01 |
| NCT03717480 |
Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03717480 |
Recruiting |
Dana-Farber Cancer Institute |
2022-05-01 |
| NCT03712878 |
2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT03712878 |
Recruiting |
Thomas Jefferson University |
2020-12-31 |
| NCT03699631 |
PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant |
https://ClinicalTrials.gov/show/NCT03699631 |
Active, not recruiting |
Medical College of Wisconsin |
2021-02-01 |
| NCT03680092 |
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation in Patients With Hematologic Malignancy |
https://ClinicalTrials.gov/show/NCT03680092 |
Recruiting |
University of California, San Diego |
2020-08-31 |
| NCT03654404 |
Development of a Positive Psychology Intervention to Improve Mood and HRQoL in Patients Post-HSCT - Proof of Concept |
https://ClinicalTrials.gov/show/NCT03654404 |
Recruiting |
Dana-Farber Cancer Institute |
2020-06-30 |
| NCT03648372 |
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19) |
https://ClinicalTrials.gov/show/NCT03648372 |
Recruiting |
Takeda |
2021-02-16 |
| NCT03598608 |
Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) |
https://ClinicalTrials.gov/show/NCT03598608 |
Recruiting |
Merck Sharp & Dohme Corp. |
2025-11-05 |
| NCT03588936 |
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant |
https://ClinicalTrials.gov/show/NCT03588936 |
Active, not recruiting |
Medical College of Wisconsin |
2021-08-01 |
| NCT03588598 |
Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03588598 |
Recruiting |
Nanjing Sanhome Pharmaceutical, Co., Ltd. |
2019-07-31 |
| NCT03580655 |
(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis |
https://ClinicalTrials.gov/show/NCT03580655 |
Recruiting |
Blueprint Medicines Corporation |
2022-05-31 |
| NCT03557619 |
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT03557619 |
Recruiting |
AbbVie |
2021-06-04 |
| NCT03555955 |
A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 |
https://ClinicalTrials.gov/show/NCT03555955 |
Recruiting |
Jazz Pharmaceuticals |
2021-01-31 |
| NCT03537482 |
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03537482 |
Recruiting |
Ascentage Pharma Group Inc. |
2020-09-15 |
| NCT03531736 |
T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia |
https://ClinicalTrials.gov/show/NCT03531736 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-05-31 |
| NCT03512340 |
Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers |
https://ClinicalTrials.gov/show/NCT03512340 |
Active, not recruiting |
Surface Oncology |
2020-09-18 |
| NCT03483324 |
Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation |
https://ClinicalTrials.gov/show/NCT03483324 |
Recruiting |
Angiocrine Bioscience |
2020-06-30 |
| NCT03483194 |
Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH) |
https://ClinicalTrials.gov/show/NCT03483194 |
Completed |
Weprom |
2020-04-20 |
| NCT03471260 |
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Participants With IDH1 Mutated Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03471260 |
Recruiting |
M.D. Anderson Cancer Center |
2021-09-30 |
| NCT03459170 |
Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant |
https://ClinicalTrials.gov/show/NCT03459170 |
Recruiting |
Bellicum Pharmaceuticals |
2020-03-31 |
| NCT03434704 |
Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole |
https://ClinicalTrials.gov/show/NCT03434704 |
Recruiting |
IRCCS San Raffaele |
2020-03-15 |
| NCT03431090 |
Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia |
https://ClinicalTrials.gov/show/NCT03431090 |
Recruiting |
Nationwide Children’s Hospital |
2021-12-31 |
| NCT03422679 |
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies |
https://ClinicalTrials.gov/show/NCT03422679 |
Recruiting |
Cellestia Biotech AG |
2021-06-30 |
| NCT03413800 |
Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT03413800 |
Recruiting |
Ciusss de L’Est de l’ÃŽle de Montréal |
2021-01-29 |
| NCT01260545 |
Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01260545 |
Completed |
XBiotech, Inc. |
2012-06-30 |
| NCT01254630 |
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011) |
https://ClinicalTrials.gov/show/NCT01254630 |
Completed |
Merck Sharp & Dohme Corp. |
2017-04-11 |
| NCT01247701 |
Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01247701 |
Active, not recruiting |
Baylor College of Medicine |
2024-11-30 |
| NCT01246206 |
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT |
https://ClinicalTrials.gov/show/NCT01246206 |
Completed |
Barbara Ann Karmanos Cancer Institute |
2013-10-31 |
| NCT01244906 |
Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant |
https://ClinicalTrials.gov/show/NCT01244906 |
Completed |
Northside Hospital, Inc. |
2014-04-30 |
| NCT01237639 |
Study of Red Blood Cell Transfusion Triggers in Patients Undergoing Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT01237639 |
Completed |
Ottawa Hospital Research Institute |
2016-10-31 |
| NCT01231412 |
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01231412 |
Completed |
Fred Hutchinson Cancer Research Center |
2016-10-08 |
| NCT01221857 |
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01221857 |
Completed |
Gamida Cell ltd |
2012-09-30 |
| NCT01204164 |
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01204164 |
Completed |
Tragara Pharmaceuticals, Inc. |
2016-03-31 |
| NCT01203722 |
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01203722 |
Recruiting |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2023-09-30 |
| NCT01195311 |
A Dose-escalation Study in Subjects With Advanced Malignancies |
https://ClinicalTrials.gov/show/NCT01195311 |
Completed |
Incyte Corporation |
2013-05-31 |
| NCT01188798 |
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01188798 |
Completed |
St. Jude Children’s Research Hospital |
2012-02-29 |
| NCT01186809 |
Cytokine Induced Killer (CIK) Cells In Leukemia Patients |
https://ClinicalTrials.gov/show/NCT01186809 |
Completed |
A.O. Ospedale Papa Giovanni XXIII |
2016-09-30 |
| NCT01175785 |
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01175785 |
Completed |
Nohla Therapeutics, Inc. |
2014-08-31 |
| NCT01162096 |
Reduced Intensity Haploidentical Transplant for Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01162096 |
Completed |
Thomas Jefferson University |
2010-09-30 |
| NCT01139151 |
4’-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01139151 |
Completed |
M.D. Anderson Cancer Center |
2011-11-30 |
| NCT01119066 |
HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01119066 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-05-31 |
| NCT01110473 |
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01110473 |
Completed |
AbbVie |
2013-06-30 |
| NCT01093586 |
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01093586 |
Completed |
Case Comprehensive Cancer Center |
2015-12-31 |
| NCT01086735 |
Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT01086735 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2012-11-30 |
| NCT01084252 |
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01084252 |
Active, not recruiting |
Sanofi |
2018-12-21 |
| NCT01081405 |
Total Lymphoid Irradiation and Anti-Thymocyte Globulin in the Allogeneic Hematopoietic Cell Transplantation |
https://ClinicalTrials.gov/show/NCT01081405 |
Recruiting |
Fondazione Neoplasie Sangue Onlus |
2020-11-30 |
| NCT01063647 |
Dose-range Finding Treosulfan-based Conditioning |
https://ClinicalTrials.gov/show/NCT01063647 |
Completed |
medac GmbH |
2005-06-30 |
| NCT01036009 |
A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01036009 |
Completed |
University of California, San Francisco |
2014-07-31 |
| NCT01034475 |
Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given Twice Weekly for Three Consecutive Weeks in Patients With Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01034475 |
Completed |
Wake Forest University Health Sciences |
2013-06-30 |
| NCT01010217 |
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide |
https://ClinicalTrials.gov/show/NCT01010217 |
Completed |
M.D. Anderson Cancer Center |
2017-10-05 |
| NCT00997386 |
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States |
https://ClinicalTrials.gov/show/NCT00997386 |
Completed |
University of Arizona |
2014-04-30 |
| NCT00993486 |
Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor |
https://ClinicalTrials.gov/show/NCT00993486 |
Completed |
Kiadis Pharma |
2008-10-31 |
| NCT00990717 |
Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00990717 |
Completed |
University Health Network, Toronto |
2012-07-31 |
| NCT00990587 |
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy |
https://ClinicalTrials.gov/show/NCT00990587 |
Completed |
University Health Network, Toronto |
2013-05-31 |
| NCT00987987 |
Amplifying Graft-Versus-Tumor Effect by Donor Regulatory T-Cell Depletion Before Donor Lymphocytes Infusion |
https://ClinicalTrials.gov/show/NCT00987987 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2009-12-31 |
| NCT00968630 |
Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00968630 |
Completed |
Fred Hutchinson Cancer Research Center |
2017-03-17 |
| NCT00953758 |
A Study Of PF-04449913 In Select Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00953758 |
Completed |
Pfizer |
2012-09-30 |
| NCT00943592 |
Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00943592 |
Completed |
University of Chicago |
2011-04-30 |
| NCT00943319 |
Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00943319 |
Completed |
University of Chicago |
2017-12-31 |
| NCT00914849 |
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00914849 |
Completed |
Washington University School of Medicine |
2011-01-31 |
| NCT00908167 |
Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00908167 |
Completed |
St. Jude Children’s Research Hospital |
2015-06-30 |
| NCT00904787 |
Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00904787 |
Completed |
CASI Pharmaceuticals, Inc. |
2010-12-31 |
| NCT00900614 |
Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer |
https://ClinicalTrials.gov/show/NCT00900614 |
Completed |
Aprea Therapeutics |
2010-10-31 |
| NCT00897260 |
Umbilical Cord Blood Transplantation As Treatment Of Adult Patients With Hematologic Disorders |
https://ClinicalTrials.gov/show/NCT00897260 |
Completed |
University of British Columbia |
2013-01-09 |
| NCT00894049 |
A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation |
https://ClinicalTrials.gov/show/NCT00894049 |
Completed |
Institut Paoli-Calmettes |
2013-02-28 |
| NCT00893555 |
Pharmacologic Optimization of Voriconazole |
https://ClinicalTrials.gov/show/NCT00893555 |
Completed |
University Medical Center Groningen |
2016-11-30 |
| NCT00892502 |
Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy? |
https://ClinicalTrials.gov/show/NCT00892502 |
Completed |
Copenhagen University Hospital at Herlev |
2012-01-31 |
| NCT00891137 |
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy |
https://ClinicalTrials.gov/show/NCT00891137 |
Completed |
Cellerant Therapeutics |
2014-06-30 |
| NCT00890500 |
Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies. |
https://ClinicalTrials.gov/show/NCT00890500 |
Completed |
Fate Therapeutics |
2013-05-31 |
| NCT00881946 |
Repeat Dose Safety Study for Compound to Treat Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00881946 |
Completed |
Accenture |
2012-03-31 |
| NCT00867230 |
FTS Study in Patients With Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00867230 |
Completed |
M.D. Anderson Cancer Center |
2009-02-28 |
| NCT00845819 |
Study of Epidermal Growth Factor on Oral Mucositis Induced by Intensive Chemotherapy for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00845819 |
Completed |
Seoul National University Hospital |
2014-10-31 |
| NCT00843947 |
Reduced Intensity Stem Cell Transplantation (RIST) for Patients With Hematological Malignancies Conditioned With Fludarabine and Busulfan |
https://ClinicalTrials.gov/show/NCT00843947 |
Completed |
University of California, Davis |
2013-11-30 |
| NCT00841724 |
Study of a Reduced-toxicity “Submyeloablative” Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00841724 |
Completed |
Nantes University Hospital |
2012-01-31 |
| NCT00840190 |
A Study Of Selective Cyclin Dependent Kinase Inhibitor P1446A-05 In Subjects With Advanced Refractory Malignancies |
https://ClinicalTrials.gov/show/NCT00840190 |
Completed |
Piramal Enterprises Limited |
2011-03-31 |
| NCT03711604 |
Compassionate Use Study of Tenalisib (RP6530) |
https://ClinicalTrials.gov/show/NCT03711604 |
Enrolling by invitation |
Rhizen Pharmaceuticals SA |
2020-10-31 |
| NCT02458235 |
Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02458235 |
Active, not recruiting |
University of California, San Francisco |
2020-03-31 |
| NCT00825487 |
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00825487 |
Completed |
ArQule |
2011-05-31 |
| NCT00824993 |
Prevention of Osteoporosis in Bone Marrow Transplantation (BMT) Patients |
https://ClinicalTrials.gov/show/NCT00824993 |
Completed |
M.D. Anderson Cancer Center |
2017-04-07 |
| NCT00824135 |
Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00824135 |
Completed |
St. Jude Children’s Research Hospital |
2012-10-31 |
| NCT02921685 |
Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02921685 |
Recruiting |
Institut Paoli-Calmettes |
2019-05-28 |
| NCT00810602 |
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00810602 |
Completed |
University of Michigan Rogel Cancer Center |
2013-04-30 |
| NCT00807677 |
A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00807677 |
Completed |
Millennium Pharmaceuticals, Inc. |
2012-09-30 |
| NCT01949545 |
Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment |
https://ClinicalTrials.gov/show/NCT01949545 |
Completed |
Amgen |
2015-08-31 |
| NCT01399840 |
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01399840 |
Completed |
Pfizer |
2014-03-31 |
| NCT03878524 |
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial |
https://ClinicalTrials.gov/show/NCT03878524 |
Recruiting |
OHSU Knight Cancer Institute |
2022-02-27 |
| NCT01822509 |
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01822509 |
Active, not recruiting |
National Cancer Institute (NCI) |
2018-12-31 |
| NCT04303091 |
The Feasibility of a Physical Activity Intervention for Advanced Multiple Myeloma Patients |
https://ClinicalTrials.gov/show/NCT04303091 |
Completed |
University of Calgary |
2018-12-20 |
| NCT03262220 |
Total Marrow Irradiation With Volumetric Arc Therapy for Patients Unfit for a 12 Gy TBI |
https://ClinicalTrials.gov/show/NCT03262220 |
Recruiting |
University Hospital, Geneva |
2021-04-30 |
| NCT03082677 |
Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03082677 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-03-31 |
| NCT02730299 |
Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard Umbilical Cord Blood in Patients With Leukemia, Lymphoma, and Myelodysplastic Syndrome (MDS) |
https://ClinicalTrials.gov/show/NCT02730299 |
Active, not recruiting |
Gamida Cell ltd |
2019-12-31 |
| NCT02566395 |
Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02566395 |
Recruiting |
Northwell Health |
2021-12-31 |
| NCT02528682 |
MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT |
https://ClinicalTrials.gov/show/NCT02528682 |
Recruiting |
Radboud University |
2020-05-31 |
| NCT03241550 |
A Study of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients |
https://ClinicalTrials.gov/show/NCT03241550 |
Completed |
Astellas Pharma Inc |
2019-07-05 |
| NCT01300026 |
AMG 319 Lymphoid Malignancy FIH |
https://ClinicalTrials.gov/show/NCT01300026 |
Completed |
Amgen |
2013-10-31 |
| NCT01816230 |
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM |
https://ClinicalTrials.gov/show/NCT01816230 |
Completed |
Gamida Cell ltd |
2017-06-30 |
| NCT03894150 |
A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies. |
https://ClinicalTrials.gov/show/NCT03894150 |
Recruiting |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. |
2021-03-01 |
| NCT03838926 |
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03838926 |
Recruiting |
Vanda Pharmaceuticals |
2020-08-31 |
| NCT00886522 |
Intrabone Infusion of Cord Blood in Adults With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00886522 |
Completed |
St. Orsola Hospital |
2012-05-31 |
| NCT00788684 |
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers |
https://ClinicalTrials.gov/show/NCT00788684 |
Active, not recruiting |
AbbVie |
2022-05-02 |
| NCT00780052 |
Infusional C-myb ASODN in Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00780052 |
Completed |
Abramson Cancer Center of the University of Pennsylvania |
2011-08-31 |
| NCT00763490 |
Trial Of Double Umbilical Cord Blood Transplantation |
https://ClinicalTrials.gov/show/NCT00763490 |
Completed |
University of Michigan Rogel Cancer Center |
2013-03-31 |
| NCT00750737 |
Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) |
https://ClinicalTrials.gov/show/NCT00750737 |
Completed |
M.D. Anderson Cancer Center |
2012-06-30 |
| NCT00749502 |
A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) |
https://ClinicalTrials.gov/show/NCT00749502 |
Completed |
Tesaro, Inc. |
2011-09-30 |
| NCT00742560 |
A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00742560 |
Completed |
AbbVie |
2016-10-31 |
| NCT00741455 |
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00741455 |
Active, not recruiting |
Dartmouth-Hitchcock Medical Center |
2023-01-31 |
| NCT00741234 |
A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine |
https://ClinicalTrials.gov/show/NCT00741234 |
Completed |
S*BIO |
2012-03-31 |
| NCT00739141 |
Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. |
https://ClinicalTrials.gov/show/NCT00739141 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2020-08-31 |
| NCT00722488 |
Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00722488 |
Completed |
Millennium Pharmaceuticals, Inc. |
2013-07-31 |
| NCT00718757 |
Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00718757 |
Completed |
St. Jude Children’s Research Hospital |
2009-01-31 |
| NCT00710528 |
Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00710528 |
Completed |
Gilead Sciences |
2011-12-31 |
| NCT00697671 |
Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00697671 |
Completed |
St. Jude Children’s Research Hospital |
2013-02-28 |
| NCT00697346 |
Study of MLN8237 in Participants With Advanced Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00697346 |
Completed |
Takeda |
2016-10-01 |
| NCT00693927 |
Nonmyeloablative Stem Cell Transplantation With CD8-depleted or Unmanipulated Peripheral Blood Stem Cells (PBSC) |
https://ClinicalTrials.gov/show/NCT00693927 |
Completed |
University of Liege |
2005-05-31 |
| NCT00683046 |
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00683046 |
Completed |
University of Chicago |
2014-12-31 |
| NCT00677859 |
Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia |
https://ClinicalTrials.gov/show/NCT00677859 |
Completed |
Athersys, Inc |
2011-10-31 |
| NCT00674479 |
INCB018424 in Patients With Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00674479 |
Completed |
M.D. Anderson Cancer Center |
2017-03-23 |
| NCT00673114 |
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies |
https://ClinicalTrials.gov/show/NCT00673114 |
Completed |
Duke University |
2012-04-30 |
| NCT00660920 |
Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00660920 |
Completed |
Takeda |
2016-05-31 |
| NCT00642031 |
Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00642031 |
Completed |
Prescient Therapeutics, Ltd. |
2012-10-31 |
| NCT00640796 |
Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors |
https://ClinicalTrials.gov/show/NCT00640796 |
Completed |
St. Jude Children’s Research Hospital |
2014-04-30 |
| NCT00623870 |
A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms. |
https://ClinicalTrials.gov/show/NCT00623870 |
Completed |
Hoffmann-La Roche |
2012-11-30 |
| NCT00621244 |
A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00621244 |
Completed |
Novartis |
2009-12-03 |
| NCT00618969 |
Peripheral Blood Stem Cell Transplantation (PBSCT)From Haploidentical Related Donors |
https://ClinicalTrials.gov/show/NCT00618969 |
Completed |
University of Arizona |
2013-12-31 |
| NCT00597519 |
A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy |
https://ClinicalTrials.gov/show/NCT00597519 |
Completed |
Memorial Sloan Kettering Cancer Center |
2015-09-30 |
| NCT00595686 |
Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00595686 |
Completed |
Esanex Inc. |
2010-05-31 |
| NCT00592046 |
A Phase I Trial of ZIO-101 in Hematologic Cancers |
https://ClinicalTrials.gov/show/NCT00592046 |
Completed |
Ziopharm |
2008-06-30 |
| NCT00582894 |
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases |
https://ClinicalTrials.gov/show/NCT00582894 |
Completed |
University of Oklahoma |
2008-03-31 |
| NCT00558675 |
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy |
https://ClinicalTrials.gov/show/NCT00558675 |
Completed |
Immunovative Therapies, Ltd. |
2012-12-31 |
| NCT00557817 |
Erythropoietin (Epo) and Venofer Trial After Autologous Hematopoietic Stem Cell Transplantation (HSCT) |
https://ClinicalTrials.gov/show/NCT00557817 |
Completed |
University of Liege |
2008-08-31 |
| NCT00556452 |
Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen |
https://ClinicalTrials.gov/show/NCT00556452 |
Completed |
University of Michigan Rogel Cancer Center |
2011-06-30 |
| NCT00533078 |
Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00533078 |
Completed |
University Hospital Inselspital, Berne |
2009-12-31 |
| NCT00526045 |
Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients |
https://ClinicalTrials.gov/show/NCT00526045 |
Completed |
Novartis |
2012-04-30 |
| NCT00521859 |
Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00521859 |
Completed |
M.D. Anderson Cancer Center |
2010-12-31 |
| NCT00514579 |
Adult Double Cord Blood Transplant Study |
https://ClinicalTrials.gov/show/NCT00514579 |
Completed |
Center for International Blood and Marrow Transplant Research |
2013-08-31 |
| NCT00506857 |
Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support |
https://ClinicalTrials.gov/show/NCT00506857 |
Completed |
M.D. Anderson Cancer Center |
2011-08-31 |
| NCT00506402 |
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00506402 |
Completed |
CASI Pharmaceuticals, Inc. |
2009-01-31 |
| NCT00504803 |
Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease |
https://ClinicalTrials.gov/show/NCT00504803 |
Completed |
University of Liege |
2010-12-31 |
| NCT00500578 |
Intermittent Use of Aerosolized Ribavirin for Treatment of RSV |
https://ClinicalTrials.gov/show/NCT00500578 |
Completed |
M.D. Anderson Cancer Center |
2009-01-31 |
| NCT00496340 |
Phase II Trial of Pentostatin and Targeted Busulfan |
https://ClinicalTrials.gov/show/NCT00496340 |
Completed |
H. Lee Moffitt Cancer Center and Research Institute |
2013-04-30 |
| NCT00477542 |
A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCT |
https://ClinicalTrials.gov/show/NCT00477542 |
Completed |
Indiana University |
2010-11-30 |
| NCT00477035 |
Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00477035 |
Completed |
Stanford University |
2011-03-31 |
| NCT00476177 |
Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant |
https://ClinicalTrials.gov/show/NCT00476177 |
Completed |
Dana-Farber Cancer Institute |
2007-08-31 |
| NCT00473577 |
Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients |
https://ClinicalTrials.gov/show/NCT00473577 |
Completed |
Pharmacyclics LLC. |
2007-11-30 |
| NCT00472368 |
A Study to Determine the Absorption, Distribution, Metabolism, and Excretion of LBH589 |
https://ClinicalTrials.gov/show/NCT00472368 |
Completed |
Novartis |
2008-06-30 |
| NCT00469729 |
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy |
https://ClinicalTrials.gov/show/NCT00469729 |
Completed |
Gamida Cell -Teva Joint Venture Ltd. |
2013-02-28 |
| NCT00460694 |
Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies |
https://ClinicalTrials.gov/show/NCT00460694 |
Completed |
Singapore General Hospital |
2012-12-31 |
| NCT00438178 |
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00438178 |
Completed |
Teva Pharmaceutical Industries |
2007-10-31 |
| NCT00430846 |
Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00430846 |
Completed |
Seattle Genetics, Inc. |
2009-07-31 |
| NCT00429416 |
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00429416 |
Completed |
Thomas Jefferson University |
2008-12-31 |
| NCT00429143 |
A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative |
https://ClinicalTrials.gov/show/NCT00429143 |
Completed |
Thomas Jefferson University |
2009-08-31 |
| NCT00423124 |
Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies |
https://ClinicalTrials.gov/show/NCT00423124 |
Completed |
MolMed S.p.A. |
2011-12-31 |
| NCT00421213 |
Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers |
https://ClinicalTrials.gov/show/NCT00421213 |
Completed |
Ziopharm |
2012-04-30 |
| NCT00820560 |
Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors |
https://ClinicalTrials.gov/show/NCT00820560 |
Completed |
Incyte Corporation |
2009-01-31 |
| NCT00410696 |
Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy |
https://ClinicalTrials.gov/show/NCT00410696 |
Completed |
Istituto Clinico Humanitas |
2008-11-30 |
| NCT00405743 |
A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00405743 |
Completed |
Clavis Pharma |
2009-05-31 |
| NCT00402714 |
A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies |
https://ClinicalTrials.gov/show/NCT00402714 |
Completed |
Yale University |
2009-07-31 |
| NCT00389428 |
Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer. |
https://ClinicalTrials.gov/show/NCT00389428 |
Completed |
Jazz Pharmaceuticals |
2008-12-31 |
| NCT00382759 |
Nonmyeloablative Stem Cell Transplant in Elderly |
https://ClinicalTrials.gov/show/NCT00382759 |
Completed |
Azienda Ospedaliera San Giovanni Battista |
2007-03-31 |
| NCT00379587 |
Rituximab for Prevention of Chronic GVHD |
https://ClinicalTrials.gov/show/NCT00379587 |
Completed |
Dana-Farber Cancer Institute |
2012-08-31 |
| NCT00369226 |
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00369226 |
Completed |
Dana-Farber Cancer Institute |
2010-07-31 |
| NCT00367588 |
Low Bacterial Diet in Patients With Cytopenia |
https://ClinicalTrials.gov/show/NCT00367588 |
Completed |
Maastricht University Medical Center |
NA |
| NCT00355407 |
Darbepoetin Alfa (Aranesp) Following Allogeneic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00355407 |
Completed |
Dana-Farber Cancer Institute |
2007-08-31 |
| NCT00348959 |
An Evaluation of the Effect of ‘Open Window’ on Psychological Well-being and Experience of Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00348959 |
Completed |
St. James’s Hospital, Ireland |
2010-01-31 |
| NCT00343798 |
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00343798 |
Completed |
Fred Hutchinson Cancer Research Center |
2013-07-31 |
| NCT00333190 |
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00333190 |
Completed |
Dana-Farber Cancer Institute |
2007-03-31 |
| NCT00312429 |
Umbilical Cord Blood Stem Cell Transplantation in Adults With Advanced Blood Disorders or Cancer |
https://ClinicalTrials.gov/show/NCT00312429 |
Completed |
Duke University |
2008-05-31 |
| NCT00273936 |
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00273936 |
Completed |
Vertex Pharmaceuticals Incorporated |
NA |
| NCT00270881 |
Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00270881 |
Completed |
Keio University |
2009-01-31 |
| NCT00246662 |
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00246662 |
Completed |
Sunesis Pharmaceuticals |
2008-12-23 |
| NCT00241358 |
Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00241358 |
Completed |
Washington University School of Medicine |
2009-12-31 |
| NCT00231309 |
Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT) |
https://ClinicalTrials.gov/show/NCT00231309 |
Completed |
Emory University |
2011-11-30 |
| NCT00208962 |
Allogeneic Cell Therapy for Adults With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00208962 |
Completed |
Emory University |
2007-09-30 |
| NCT00208923 |
Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00208923 |
Completed |
Emory University |
2007-10-31 |
| NCT00202917 |
Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00202917 |
Completed |
University Hospital Tuebingen |
2009-07-31 |
| NCT00189488 |
Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation |
https://ClinicalTrials.gov/show/NCT00189488 |
Completed |
Swedish Orphan Biovitrum |
2008-11-30 |
| NCT00186823 |
Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00186823 |
Completed |
St. Jude Children’s Research Hospital |
2005-09-30 |
| NCT00186342 |
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00186342 |
Completed |
Stanford University |
2009-01-31 |
| NCT00186225 |
Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors |
https://ClinicalTrials.gov/show/NCT00186225 |
Completed |
Stanford University |
2007-06-30 |
| NCT00185640 |
Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00185640 |
Completed |
Stanford University |
2014-04-30 |
| NCT00179764 |
Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC]) |
https://ClinicalTrials.gov/show/NCT00179764 |
Completed |
Ann & Robert H Lurie Children’s Hospital of Chicago |
2014-01-24 |
| NCT00165282 |
Mindfulness Meditation in Bone Marrow Transplantation |
https://ClinicalTrials.gov/show/NCT00165282 |
Completed |
Emory University |
2010-01-31 |
| NCT00152139 |
Stem Cell Transplantation for Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00152139 |
Completed |
St. Jude Children’s Research Hospital |
2005-06-30 |
| NCT00150462 |
Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00150462 |
Completed |
Amgen |
2009-10-31 |
| NCT00146614 |
Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00146614 |
Completed |
Dana-Farber Cancer Institute |
2003-04-30 |
| NCT00145626 |
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00145626 |
Completed |
St. Jude Children’s Research Hospital |
2015-03-31 |
| NCT00145613 |
Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00145613 |
Completed |
St. Jude Children’s Research Hospital |
2006-07-31 |
| NCT00144703 |
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00144703 |
Completed |
Dana-Farber Cancer Institute |
2006-11-30 |
| NCT00143559 |
Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00143559 |
Completed |
St. Jude Children’s Research Hospital |
2006-07-31 |
| NCT00138112 |
Trial of Prophylactic Versus Empirical Vancomycin for the Prevention of Streptococcal Sepsis After Hematopoietic Cell Transplantation |
https://ClinicalTrials.gov/show/NCT00138112 |
Completed |
Memorial Sloan Kettering Cancer Center |
NA |
| NCT00003395 |
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00003395 |
Completed |
Memorial Sloan Kettering Cancer Center |
2000-03-31 |
| NCT00088101 |
STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors |
https://ClinicalTrials.gov/show/NCT00088101 |
Completed |
Synta Pharmaceuticals Corp. |
NA |
| NCT00086125 |
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) |
https://ClinicalTrials.gov/show/NCT00086125 |
Completed |
Merck Sharp & Dohme Corp. |
2006-06-30 |
| NCT00080925 |
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00080925 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00005799 |
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer |
https://ClinicalTrials.gov/show/NCT00005799 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-07-31 |
| NCT00079391 |
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies |
https://ClinicalTrials.gov/show/NCT00079391 |
Completed |
National Institutes of Health Clinical Center (CC) |
2008-12-31 |
| NCT00078858 |
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00078858 |
Completed |
Fred Hutchinson Cancer Research Center |
2006-01-31 |
| NCT00077181 |
3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00077181 |
Completed |
National Cancer Institute (NCI) |
2008-07-31 |
| NCT00070538 |
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00070538 |
Completed |
National Cancer Institute (NCI) |
2004-09-30 |
| NCT00068523 |
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00068523 |
Completed |
Case Comprehensive Cancer Center |
2004-03-31 |
| NCT00067730 |
A Safety Evaluation of Drotrecogin Alfa (Activated) in Patients With Blood Cancer, Severe Infection Related to Bone Marrow Transplantation |
https://ClinicalTrials.gov/show/NCT00067730 |
Completed |
Eli Lilly and Company |
NA |
| NCT00061620 |
Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00061620 |
Completed |
M.D. Anderson Cancer Center |
2004-02-12 |
| NCT00056966 |
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases |
https://ClinicalTrials.gov/show/NCT00056966 |
Completed |
Baylor College of Medicine |
2005-05-31 |
| NCT00027820 |
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer |
https://ClinicalTrials.gov/show/NCT00027820 |
Completed |
Fred Hutchinson Cancer Research Center |
2004-09-30 |
| NCT00006379 |
Non-Ablative Allo HSCT For Hematologic Malignancies or SAA |
https://ClinicalTrials.gov/show/NCT00006379 |
Completed |
Case Comprehensive Cancer Center |
2004-01-31 |
| NCT00051597 |
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00051597 |
Completed |
Seattle Genetics, Inc. |
NA |
| NCT00051311 |
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers |
https://ClinicalTrials.gov/show/NCT00051311 |
Completed |
National Institutes of Health Clinical Center (CC) |
2014-09-25 |
| NCT00001748 |
HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00001748 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00047489 |
Study of ABT-751 in Patients With Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00047489 |
Completed |
M.D. Anderson Cancer Center |
2005-01-31 |
| NCT00044759 |
Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma |
https://ClinicalTrials.gov/show/NCT00044759 |
Completed |
Wyeth is now a wholly owned subsidiary of Pfizer |
NA |
| NCT00795132 |
Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00795132 |
Completed |
University of Utah |
2009-07-31 |
| NCT00042250 |
IUdR/BUdR Cell Cycle Labelling |
https://ClinicalTrials.gov/show/NCT00042250 |
Completed |
M.D. Anderson Cancer Center |
2002-10-31 |
| NCT00041665 |
Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy |
https://ClinicalTrials.gov/show/NCT00041665 |
Completed |
Amgen |
NA |
| NCT00038376 |
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies |
https://ClinicalTrials.gov/show/NCT00038376 |
Completed |
M.D. Anderson Cancer Center |
2005-06-30 |
| NCT00028418 |
Clofarabine in Chronic Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT00028418 |
Completed |
FDA Office of Orphan Products Development |
NA |
| NCT00603954 |
Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings |
https://ClinicalTrials.gov/show/NCT00603954 |
Completed |
University of Liege |
2011-03-31 |
| NCT00675831 |
Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00675831 |
Completed |
Dana-Farber Cancer Institute |
2013-01-31 |
| NCT00013533 |
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies |
https://ClinicalTrials.gov/show/NCT00013533 |
Completed |
National Institutes of Health Clinical Center (CC) |
2008-03-01 |
| NCT00005785 |
Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer |
https://ClinicalTrials.gov/show/NCT00005785 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00001873 |
The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers |
https://ClinicalTrials.gov/show/NCT00001873 |
Completed |
National Institutes of Health Clinical Center (CC) |
2007-12-28 |
| NCT00001623 |
Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia |
https://ClinicalTrials.gov/show/NCT00001623 |
Completed |
National Institutes of Health Clinical Center (CC) |
2008-01-31 |